Apart from eye drops and surgery, another therapy used to treat refractory glaucoma is ciliary body destruction. Several energy sources and different techniques for destroying ciliary body processes have been studied by researchers. These include diathermy, cryotherapy, diode or neodymium-doped yttrium aluminium garnet (Nd:YAG) laser and ultrasound via the transscleral route, [4] [5] [6] [7] transpupillary cyclophotocoagulation 8 and intraocular endophotocoagulation. 9 The conventional clinical treatment is diode laser transscleral cyclophotocoagulation, comprising partially destroying ciliary body processes and reducing production of aqueous humour and intraocular pressure. [10] [11] [12] However, laser cyclophotocoagulation has low selectivity for ciliary body processes and, although effective, is not well tolerated. Destruction of surrounding tissue causes complications, such as hypotony, phthisis, hyphaema, scleromalacia, uveal reactions, ocular pain and discomfort, and ocular inflammation followed by vision loss, and repeated sessions are required. Laser cyclophotocoagulation is currently reserved for cases of patients with highly advanced glaucoma and poor vision. [13] [14] [15] [16] [17] [18] n Early clinical and preclinical trials of ultrasonic coagulation of the ciliary body using high intensity focused ultrasound (HIFU) demonstrated that cyclodestruction using this method is effective in lowering high intraocular pressure (IOP). 5, 19 In a multicentre trial of therapeutic ultrasound for glaucoma where treatments were performed on 880 eyes, the one-year multi-treatment success rate was 79.3 % when retreatment was used following treatment failure. 20 A clinical series performed with the commercial SonoCare™ Therapeutic Ultrasound System Model demonstrated that this process was effective in reducing IOP. [21] [22] [23] A benefit of ultrasound over laser is that the energy can be focused through non-optically transparent media to produce controlled thermocoagulation, without the effects of explosive disruption on surrounding tissue. Ultrasound effects are predictable, since tissue heating and energy deposition at the focus are independent of pigmentation quantity, a variable parameter in the ciliary body.
Focused ultrasound can be used to treat tissue volumes at any site or depth in the eye. 24 Despite the efficacy of HIFU, its use for ciliary body destruction was abandoned in the mid-1990s, partly due to the bulky design of the commercial system and relative complexity of the process. The distance of the large transducer from the eye had to be measured.
Each HIFU exposure created a single pinpoint lesion. [25] [26] [27] HIFU can now be carried out using miniaturised transducers, which produce small focal regions and give improved targeting and control of therapy zones, especially in small organs such as the ciliary body.
More complex transducers allow the creation of lesions of variable geometry, which can be used to treat hard-to-access tumours. In an ideal situation, glaucoma is diagnosed before the symptoms are apparent, and the disease is explained to patients so that any fears they may have can be addressed. Patients worry about ultimate blindness, fear falls and a decline in their overall health condition, and are apprehensive regarding their possible involvement in motor vehicle accidents, restrictions to driving and subsequent inability to work in particular occupations. However, if it is diagnosed early, glaucoma can be treated before it has had a significant impact on patients' quality of life and they can retain useful sight for life. [35] [36] [37] [38] [39] As patients generally do not report symptoms until advanced damage has occurred, glaucoma is usually detected at a late stage, A study to develop a novel miniaturised device that allows safe, rapid and easy treatment of glaucoma using high intensity focused ultrasound (HIFU) cyclocoagulation was undertaken to create a one-step, accurate procedure allowing the whole circumference of the ciliary body to be treated. The strategy adopted, Ultrasound Circular Cyclo-Coagulation (UC 3 ), capitalises on the circular symmetry of the eyeball to treat the ciliary body.
The device did not exceed the dimensions of the eye and treatment conformed to the ciliary body. The circular geometry of the device
Ultrasound Circular Cyclo-Coagulation -From Theory to Therapy
A report on a presentation by Florent Aptel The current UK treatment regimen recommends first-line treatment with prostaglandin analogue or prostamide eye drops for patients newly diagnosed with early or moderate chronic open-angle glaucoma.
When this treatment is insufficient to stabilise the disease, further medication is added to the patients' regimens. Once medical treatment is no longer sufficient, laser treatment may be offered. Surgery with pharmacological augmentation is offered to patients with advanced glaucoma who are at risk of progressing to sight loss despite treatment. 49 Medical treatments have disadvantages: poor tolerance due to adverse side effects, difficulty in instilling the eye drops and lack of compliance, which all impact on patients' quality of life. Lasers and surgery are associated with risks and a significant fear factor, which again affect patients' quality of life and, although these treatments are effective for a certain time, how long their effect is sustained is disputed. The greatest negative effect on quality of life is when patients lose their driving licences, sometimes long before there is a noticeable visual loss from their perspective. [50] [51] [52] The ideal scenario for the management of glaucoma is when it is detected early, controlled without the use of eye drops or invasive techniques, and an effective, safe treatment is available in the long term. In that way, the loss of patients' driving licence can be prevented and significant impact on quality of life avoided. allowed reproducible and constant positioning. To create six line-focus beams, the device was divided into six separate cylindrical transducers. The probe was attached to the eye using a truncated cone filled with saline solution. The prototype was designed using numerical simulations, which allowed adjustment of exposure conditions and operating frequency of the device to reduce thermal injury to the ciliary body. The prototype was produced, acoustically characterised and tested in thermosensitive gel and in vivo. reduction. The histological section showed conformal treatment of the ciliary body without side effects. 53 To evaluate the histological effects and clinical outcomes of HIFU delivered by miniaturised annular transducers for ciliary body coagulation in an animal study, 18 eyes of 18 rabbits were insonified using a six-sector transducer ring. Six sectors were activated in six rabbits (group 1), five sectors were activated in six rabbits (group 2) and four sectors were activated in six rabbits (group 3). 54, 55 The IOP on day 28 after treatment was significantly reduced at which energy absorption is high, the total amount of energy required to be delivered to the eye was low. Ultrasound biomicroscopy (UBM) and complete ophthalmic examination were conducted before the procedure and one day, one week, one month, three months and six months afterwards. The following parameters were used: duration of each shot three seconds (group 1, patients 1-4) or four seconds (group 2, patients 5-12).
56,57
In group 1, IOP was reduced from a mean pre-operative value of 35.6 ± 2.5 mmHg (n=2.2 glaucoma medications) to a mean postoperative value of 27.9 ± 5.7 (n=2.2), 29.6 ± 4.9 (n=2.2), 27.3 ± 3.2 (n=3.0), 27.8 ± 9.0 (n=2.7) and 27.0 ± 4.9 (n=2.5) at one day, one week, one month, three months and six months, respectively. In group 2, IOP was reduced from a mean pre-operative value of 39.1 ± 13.2 mmHg (n=4) to a mean post-operative value of 26.9 ± 15.1 (n=4), 23.0 ± 13.1 (n=4), 24.2 ± 9.2 (n=4.2), 23.1 ± 10.6 (n=4) and 25.4 ± 6.2 (n=3.4) (see Figure 3) . 56, 57 No major intra-or post-operative complications occurred. Superficial punctate keratitis occurred in three patients and central superficial corneal ulceration in one patient. All these patients presented with a pre-operative pathological condition of the cornea. UBM demonstrated localised and reproducible cystic involution of the ciliary body in eight of the 12 eyes, no damage to the surrounding ocular tissues and a suprachoroidal fluid space in six of the 12 eyes (see Figure 4) . 56, 57 Circular coagulation of the ciliary body using HIFU delivered by a ring-shaped miniaturised transducer is an effective and well-tolerated method of reducing IOP in patients with refractory glaucoma. The single-step procedure was short (less than two minutes long), easy and accurate. 56,57 n
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Glaucoma Unit, University Hospitals of Geneva The gold-standard glaucoma treatment, trabeculectomy, is associated with many shortcomings, including high complication rates and extensive post-operative follow-up -clinicians must consider post-operative management to be of equal importance to the surgical procedure itself. 58 Evidence suggests that deep sclerectomy may offer a favourable alternative to trabeculectomy. 59, 60 Most studies report significantly lower early post-operative complications compared with trabeculectomy. However, the randomised controlled trials comparing deep sclerectomy with trabeculectomy are not conclusive when it comes to efficacy. [61] [62] [63] [64] [65] Tube shunt implants have been retained for patients at high risk of failure with trabeculectomy and patients who had previously failed trabeculectomy. However, these implants remain labour-intensive and could be associated with serious complications. 66 Severe loss of central vision has been documented to occur in 6 % of eyes post-trabeculectomy in advanced glaucoma cases. 67 Other complications that commonly occur include hypotonic maculopathy and inflammation. 68 Cataract incidence post-trabeculectomy, beside its damaging effect on vision, requires another intra-operative surgery, which could adversely affect initial trabeculectomy results. 69 The efficiency of surgery may be overemphasised compared with the need for safety. Most surgeons choose to postpone surgery, 70 due to the possible vision risk complications of classic trabeculectomy, until the late stages of glaucoma. 67, 68 There is an unmet need for predictability in surgery, which demonstrates a decline in its outcomes over time. 71 Furthermore, surgery does not meet the need for speed to maximise the utilisation of limited resources. 72 Canaloplasty may be a safer alternative to trabeculectomy; however, its extensive use is hindered by its surgical difficulty, which results in long learning curves. It is difficult to use en masse surgical treatment due to technical complexity. Another drawback is that all non-penetrating glaucoma surgery does not appear to reach its predefined target intraocular pressure in a significant percentage of cases without the post-operative utilisation of goniopuncture, which requires access to laser equipment. 73 Laser-assisted surgery used to perform deep scleral dissection in deep sclerectomy is promising, but we still lack knowledge about its medium-to long-term success rate, 74 as well as there being a marked lack of trials associated with economic assessment in glaucoma. 72 Research into stents would be useful to increase long-term success rates. 75 Trabecular micro-bypass stent surgery may meet the need for rapid implantation procedures. 
Future Developments
The EyeMUST multicentre clinical study will evaluate the effectiveness and safety of glaucoma treatment by UC 3 
